---
id: 070
title: Flucytosine Toxicity and Monitoring
category: antimicrobials
subcategory: flucytosine
tags: [flucytosine, 5-FC, bone-marrow-suppression, neutropenia, hepatotoxicity, TDM]
difficulty: medium
---

## Question

What are the major toxicities of flucytosine and how should it be monitored? Use the **"BONE Marrow + LIVER"** mnemonic.

## Answer

### **"BONE Marrow + LIVER" Mnemonic:**

**BONE Marrow:**
- **B**one marrow suppression (most serious)
- **O**ccurs with levels >100 µg/mL
- **N**eutropenia, thrombocytopenia, anemia
- **E**xacerbated by renal impairment

**LIVER:**
- **L**iver enzyme elevation (ALT/AST)
- **I**ncreased risk with high levels
- **V**ery rare hepatotoxicity
- **E**xacerbated by gut flora converting 5-FC → 5-FU
- **R**equires monitoring (CBC, LFTs weekly)

### **Major Toxicities:**

#### **1. Bone Marrow Suppression (Most Important):**

**Manifestations:**
- **Neutropenia** (most common)
- **Thrombocytopenia**
- **Anemia**

**Mechanism:**
- Gut flora converts 5-FC → **5-fluorouracil (5-FU)**
- 5-FU causes bone marrow toxicity (similar to chemotherapy)
- Humans lack cytosine deaminase, but **gut bacteria have it**

**Risk Factors:**
- **Serum levels >100 µg/mL** (main risk factor)
- **Renal impairment** (drug accumulation)
- **Prolonged therapy**
- **Concurrent myelosuppressive drugs**

#### **2. Hepatotoxicity:**

**Manifestations:**
- Elevated transaminases (ALT, AST)
- Rarely: severe hepatitis

**Associated with:**
- High serum levels (>100 µg/mL)
- Prolonged therapy

## Key Points

### **Monitoring Protocol:**

**Baseline:**
- CBC with differential
- Comprehensive metabolic panel (Cr, LFTs)
- Consider baseline 5-FC level

**During Therapy:**

| Test | Frequency | Target/Action |
|------|-----------|---------------|
| **CBC with diff** | **2-3×/week** | Watch for cytopenias |
| **LFTs** | Weekly | Monitor transaminases |
| **Creatinine** | 2-3×/week | Adjust dose if ↑ Cr |
| **5-FC levels** | 2-3×/week (if available) | **Target: 30-80 µg/mL** |

**Therapeutic Drug Monitoring:**
- **Target trough:** 30-80 µg/mL (some say 25-100 µg/mL)
- **Peak:** 2 hours post-dose
- **Toxicity risk:** Levels >100 µg/mL

### **Management of Toxicity:**

**Neutropenia (ANC <500):**
- **Reduce dose** or **hold temporarily**
- Consider G-CSF if severe
- Check 5-FC level (likely >100 µg/mL)

**Thrombocytopenia (<50,000):**
- Hold 5-FC temporarily
- Platelet transfusion if bleeding/procedure needed
- Restart at lower dose once recovered

**Hepatotoxicity (ALT/AST >5× ULN):**
- Hold 5-FC
- Check 5-FC level
- Resume at lower dose if resolves

### **Dose Adjustments:**

**Renal Impairment (Critical):**
- 5-FC is **100% renally cleared**
- **MUST adjust for any renal impairment**
- Failure to adjust → high levels → bone marrow suppression

**If Levels >100 µg/mL:**
- Hold next dose
- Recheck level in 24 hours
- Resume at **50% dose** once level <80 µg/mL

### **Clinical Pearls:**
- **Bone marrow suppression is dose-limiting** toxicity
- **Always monitor CBC 2-3×/week** (neutropenia can develop quickly)
- **Levels >100 µg/mL = toxicity risk** (bone marrow, liver)
- **Renal dosing essential** (100% renal clearance)
- **Gut flora conversion** to 5-FU causes human toxicity
- Toxicities usually **reversible** with dose reduction/discontinuation
- **TDM important** if available (target 30-80 µg/mL)

## Sources

- [StatPearls NBK557607: Flucytosine 2024]
- [Johns Hopkins ABX Guide: Flucytosine]
- [PMC3797641: Flucytosine Toxicity and Monitoring]

## Media

N/A
